[{"orgOrder":0,"company":"Elpiscience","sponsor":"Trigr","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"TR009","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Elpiscience \/ Elpiscience Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Elpiscience Biopharmaceuticals"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Greater Bay Area Homeland Development Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"ES002","moa":"CD39 ATPase","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Elpiscience \/ Greater Bay Area Homeland Development Fund","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscience \/ Greater Bay Area Homeland Development Fund"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ES005","moa":"LAG3","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ES014","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ES014","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ES009","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"ES019","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":1.74,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.74,"dosageForm":"","sponsorNew":"Elpiscience \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscience \/ Astellas Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Elpiscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims to conduct early-stage research for novel bi-specific macrophage engagers, ES019, an anti-PD-L1/SIRPα bispecific antibody, and another program.

                          Brand Name : ES019

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 27, 2023

                          Lead Product(s) : ES019

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Astellas Pharma

                          Deal Size : $1,737.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES009 specifically binds to a unique epitope on human LILRB2 and potently blocks LILRB2 binding to multiple ligands, which is investigated for the treatment of cancer.

                          Brand Name : ES009

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 26, 2023

                          Lead Product(s) : ES009

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME).

                          Brand Name : ES014

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 27, 2023

                          Lead Product(s) : ES014

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways to synergistically activates T cells for ICB-resistant cancer immunotherapy

                          Brand Name : ES014

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 22, 2022

                          Lead Product(s) : ES014

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models.

                          Brand Name : ES005

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 21, 2022

                          Lead Product(s) : ES005

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment.

                          Brand Name : ES014

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 09, 2022

                          Lead Product(s) : ES014

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES104 (asciminib) demonstrated, 42% overall response rate (ORR) based on 10 patients with Partial Responses (PRs), including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation.

                          Brand Name : ES104

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 05, 2022

                          Lead Product(s) : Asciminib,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ES002, a potentially best-in-class anti-CD39 antibody, binds to CD39 with sub-nanomolar binding affinity and effectively blocks CD39 ATPase activity. ES002 exhibits a strong efficacy in tumor growth inhibition in vivo.

                          Brand Name : ES002

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 13, 2021

                          Lead Product(s) : ES002

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Greater Bay Area Homeland Development Fund

                          Deal Size : $105.0 million

                          Deal Type : Series C Financing

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territor...

                          Brand Name : ABL001

                          Molecule Type : Large molecule

                          Upfront Cash : $7.0 million

                          January 20, 2021

                          Lead Product(s) : Asciminib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Trigr

                          Deal Size : $117.0 million

                          Deal Type : Collaboration

                          blank